High Resolution, High-speed Multimodal Ophthalmic Imaging
This study uses advanced imaging technology to take detailed pictures of the eye in people with retinitis pigmentosa, a condition that causes progressive vision loss. The high-speed, high-resolution imaging allows researchers to see eye structures in greater detail than current clinical systems, which may help them better understand how the disease develops and progresses.
Key Objective:The trial is testing whether advanced multimodal imaging can provide clearer, more detailed views of eye structures to improve understanding of retinitis pigmentosa and potentially guide future treatments.
Who to Consider:People with retinitis pigmentosa who are interested in contributing to research that could improve imaging technology and advance understanding of their condition should consider enrolling.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems are limited in resolution, speed, or access to certain structures of the eye. The use of a high-resolution imaging system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many microstructures of the eye: photoreceptors, vessels, nerve bundles in the retina, cells and nerves in the cornea. The use of a high-speed acquisition imaging system makes it possible to detect functional measurements such as the speed of blood flow. The combination of data from multiple imaging systems to obtain multimodal information is of great importance for improving the understanding of structural changes in the eye during a disease. The purpose of this project is to observe structures that are not detectable with routinely used systems.
Eligibility Criteria
Inclusion Criteria: * People over 18 * Patient with a pathology affecting the eye or healthy volunteer * Participant who signed the consent * Beneficiaries of the health insurance Exclusion Criteria: * Patients with a history of photosensitivity. * Patients who have just received a photodynamic therapy treatment ( * Patients taking drugs with photosensitivity as a side effect. * Persons with pacemakers or other implanted electronic medical device * Patients with viral conjunctivitis or any other infectious disease. * Patients with skin lesions on the neck or forehead * Patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease. * Pregnant or lactating women * Participant unable to be followed throughout the study * Vulnerable people * Subjects with predisposition to closure of the iridocorneal angle